Index

a
abciximab 286
abdominal vein
thrombosis 332–333
acenocoumarol 243 see also vitamin K antagonists
acquired hemophilia A 91 see also acquired inhibitors of coagulation
acquired inhibitors of coagulation 124–132
autoantibodies 124–125, 127
bleeding phenotype 124
clinical follow-up 132
control of bleeding episodes 130–131
diagnosis 129
differential diagnosis 129–130
epidemiology 125–127
immunomodulation 131–132
incidence 124
laboratory measures 129
management of coagulation inhibitors 130–132
pathophysiology 124–125
recognised syndromes 124
signs and symptoms 127–129
triggers 124
acquired von Willebrand syndrome see acquired inhibitors of coagulation
activated partial thromboplastin time (APTT) 8–9, 14–19, 66, 67
activated protein C resistance 321
inherited resistance (factor V Leiden) 37–38
testing 21–22
acute coronary syndromes 282–288
anticoagulant therapy 286–287
antiplatelet therapy 284–286
aspirin therapy 284–285, 286
bleeding and increased cardiac events 288
defining hemorrhagic risk 288
direct oral anticoagulants 264–265
effects of bleeding on outcome 287–288
epidemiology 282–283
fibrinolysis 283–284
outcomes 287–288
pathophysiology 283
percutaneous coronary intervention 283
therapies 283–287
acute leukemia, bleeding complications 167
acute respiratory distress syndrome (ARDS) 415
adenosine diphosphate (ADP) 44
afibrinogenemia 115–116
α, adrenergic receptor abnormalities 163
amyloidosis 66
anagrelide 219–221, 224
ANKRD26-related thrombocytopenia 139
anticardiolipin antibodies see antiphospholipid syndrome
anticoagulation see direct oral anticoagulants; heparins; vitamin K antagonists
antifibrinolytic agents, comparative studies 309
antifibrinolytic amino acids 106–107
antineutrophil cytoplasmic antibody (ANCA) vasculitis, and VTE 346–347
antiphospholipid antibodies see antiphospholipid syndrome
antiphospholipid antibodies 269–279
association with ischemic stroke 321–322
with bleeding 279
catastrophic antiphospholipid syndrome definition 269–270
diagnosis 274–276
Index

atrial fibrillation risk factor 230–232
atrial fibrillation treatment 235–236
cardiovascular disease risk factor 230, 231
features of 229
laboratory investigations 232–234
coagulation activation markers 234
coagulation factors assessment 233–234
congenital thrombophilia screening 233
fibrinolytic tests 234
homocysteine measurement 233
lupus anticoagulant and antiphospholipid antibodies 233
platelet function tests 234
routine investigations 232
sickle cell screening 233
specialized investigations 232–234
thrombin generation assessment 234
primary prevention 234
risk factors 230–232
secondary prevention 235
treatment 234–236
combined vitamin K antagonists and antiplatelet agents 236
arthrogryposis, renal dysfunction and cholestasis (ARC) syndrome 48, 55
Ashkenazi Jews, inherited coagulation disorders 70, 114, 117–118
aspirin 217, 218, 220, 221, 224
in acute coronary syndromes 284–285, 286
and clopidogrel 307
pediatric antiplatelet therapy 408
peripheral arterial disease 289
aspirin resistance 289
atherosclerotic disease, thrombosis risk 44
atrial fibrillation 282
risk of arterial thrombosis 230–232
stroke prevention 263–264
stroke risk 230–232
treatment 235–236
vitamin K antagonists (VKAs) 235
atrial fibrillation ablation and hemostasis 293
long-term management of oral anticoagulation 294
and management of novel anticoagulants 293–294
purpose and risks 293–294
atypical hemolytic uremic syndrome (aHUS) 183
complement system 185–186
diagnosis 188–189
genotype–phenotype correlations 187
inhibitory autoantibodies 186–187
noncomplement-mediated genetic causes 187
outcomes 192
pathophysiology 185–187
penetration 187
renal transplantation in aHUS 192
treatment 191
b
Bernard–Soulier syndrome 36, 47, 54, 56, 57, 70, 139, 155, 161–162, 169
Bethesda assay 68
betrixaban 253 see also direct oral anticoagulants
aprotinin 308–309, 439
arogatrob 406
arterial thrombosis 44, 229–236
approaches to investigation and management 229
bleeding patient 63–76
bleeding history 63–64
bleeding score 65
diagnostic framework 65
abnormal coagulation without bleeding history 76
bleeding with normal PT and normal APTT 75
bleeding with normal PT and prolonged APTT 70–73
bleeding with prolonged PT and normal APTT 70, 71
bleeding with prolonged PT and prolonged APTT 73–75
family history of bleeding 64
final integration of clinical and laboratory data 70–76
laboratory evaluation 66–70
activated partial thromboplastin time (APTT) 66, 67
Bethesda assay 68
bleeding time 69
coagulation laboratory testing 66
D-dimer assay 68
electron microscopy 70
euglobin clot lysis time (ECLT) 68–69
factor XIII assays 68
fibrinogen assays 68
fibrinolytic system assessment 68–69
lumiaggregometry 69–70
mixing studies 67–68
platelet aggregation testing 69–70
Platelet Function Analyzer-100 (PFA-100) 69
platelet function tests 69–70
prothrombin time (PT) 66–67
reptilase time 67
specific clotting factor assays 67–68
thrombin clotting time (TCT) 67
von Willebrand disease testing 68
whole-blood aggregometry 70
medications 64
physical examination 65–66
bleeding score 65
bleeding time 50, 69
Bolin–Jamieson syndrome 162
bone marrow transplantation 169, 215–217
Budd–Chiari syndrome 210, 215, 332–333
busulfan 218, 219
Cancer 355–371
anticoagulation and cancer survival 371
antitumor therapy prothrombotic mechanisms 366–368
arterial thrombosis 356, 357
association with coagulation abnormalities 355–356
association with thrombosis 355–356
bleeding prophylaxis and treatment 370–371
clinical manifestations of bleeding 358
clinical manifestations of thrombosis 356–358
hypercoagulable state of patients 359–362
laboratory tests 359–362
predictors of survival 361–362
predictors of thrombosis 360
risk stratification models 360–361
routine tests 359
specialized tests 359–362
nonbacterial thrombotic endocarditis (NBTE) 356, 357
novel anticoagulants 370
pathogenesis of coagulation abnormalities 362–368
platelet activation 366
potential causes of bleeding 358
primary thromboprophylaxis 368–370
risk factors for coagulation abnormalities 362–368
risk stratification models 360–361
SOMIT study 358–359
thromboprophylaxis 368–370 for cancer surgery 368–369
for medical conditions 369–370
thrombosis and occult malignancy 358–359
thrombotic microangiopathies (TMA) 356, 357
treatment of thrombosis 370
tumor cell adhesion molecules 366
tumor cell prothrombotic mechanisms 362–366
venous occlusive disease 356–358
venous thrombosis 356–357
cardiac arrhythmias, electrophysiological catheter ablation 293–294
cardiopulmonary bypass (CPB) 299
anticoagulation during 300–301
CPB circuit 301–302
effects on platelet function 168
hemostasis in 302
technical aspects 301–302
cardiothoracic surgery 299–312
with cardiopulmonary bypass (CPB) 299
without cardiopulmonary bypass (CPB) 299–300
clinical indications to reduce transfusion exposure 308
coagulation analysis 305
effects on hemostasis 299
future developments in blood and hemostatic component management 307–310
hemostatic component therapies 302–305
inappropriateness of component transfusion 303
laboratory-guided transfusion algorithm 303–304
logistical indications to reduce transfusion exposure 308
near-patient testing (NPT) 303–304
near-patient testing-based transfusion algorithms 305–307
nonstandard laboratory tests 305
patient on antiplatelet drugs 311–312
patient on oral anticoagulant therapy 312
pharmacotherapy to minimize blood loss and transfusion 308–310
preoperative assessment clinics 310–312
preoperative assessment of current medication 311–312
preoperative diagnosis of a bleeding disorder 311
preoperative treatment of anemic patients 308
problems with conventional tests of coagulation 302–305
ROTEM (rotational thrombelastometry) 305, 307
standard laboratory tests 304–305
TEG (thrombelastography) 303, 305–306, 307
transfusion after 299
transfusion practice 302–305
cardiopulmonary bypass (CPB) 299
with cardiopulmonary bypass (CPB) 299
without cardiopulmonary bypass (CPB) 299–300
clinical indications to reduce transfusion exposure 308
coagulation analysis 305
effects on hemostasis 299
future developments in blood and hemostatic component management 307–310
hemostatic component therapies 302–305
inappropriateness of component transfusion 303
laboratory-guided transfusion algorithm 303–304
logistical indications to reduce transfusion exposure 308
near-patient testing (NPT) 303–304
near-patient testing-based transfusion algorithms 305–307
nonstandard laboratory tests 305
patient on antiplatelet drugs 311–312
patient on oral anticoagulant therapy 312
pharmacotherapy to minimize blood loss and transfusion 308–310
preoperative assessment clinics 310–312
preoperative assessment of current medication 311–312
preoperative diagnosis of a bleeding disorder 311
preoperative treatment of anemic patients 308
problems with conventional tests of coagulation 302–305
ROTEM (rotational thrombelastometry) 305, 307
standard laboratory tests 304–305
TEG (thrombelastography) 303, 305–306, 307
transfusion after 299
transfusion practice 302–305
CHADS2 scoring system 230, 235
CHA2DS2VASc scoring system 230, 235
Chédiak–Higashi syndrome 48, 55, 65, 164, 165, 169
chronic kidney disease (CKD) see renal disease
Churg–Strauss disease see eosinophilic granulomatosis with polyangiitis (EGPA)
circumcision, bleeding with 63
clopidogrel 285, 286, 289–290
and aspirin 307
clopidogrel resistance 307
cardiovascular disease
atrial fibrillation 282
heart failure 282
risk factors 230, 231
risk of arterial thrombosis 230, 231
cardiovascular medicine 282–295
acute coronary syndromes 282–288
atrial fibrillation ablation 293–294
coronary artery disease (CAD) 282
electrophysiological catheter ablation 293–294
ehemostatic management challenges 282
peripheral arterial disease 288–290
transaortic valve replacement 294–295
ventricular assist devices 290–293
CHA2DS2VASc scoring system 230, 235
CHADS2 scoring system 230, 235
Chédiak–Higashi syndrome 48, 55, 65, 164, 165, 169
chronic kidney disease (CKD) see renal disease
Churg–Strauss disease see eosinophilic granulomatosis with polyangiitis (EGPA)
circumcision, bleeding with 63
clopidogrel 285, 286, 289–290
and aspirin 307
clopidogrel resistance 307
cardiovascular disease
atrial fibrillation 282
heart failure 282
risk factors 230, 231
risk of arterial thrombosis 230, 231
cardiovascular medicine 282–295
acute coronary syndromes 282–288
atrial fibrillation ablation 293–294
coronary artery disease (CAD) 282
electrophysiological catheter ablation 293–294
ehemostatic management challenges 282
peripheral arterial disease 288–290
transaortic valve replacement 294–295
ventricular assist devices 290–293
CHA2DS2VASc scoring system 230, 235
CHADS2 scoring system 230, 235
Chédiak–Higashi syndrome 48, 55, 65, 164, 165, 169
chronic kidney disease (CKD) see renal disease
Churg–Strauss disease see eosinophilic granulomatosis with polyangiitis (EGPA)
circumcision, bleeding with 63
clopidogrel 285, 286, 289–290
and aspirin 307
clopidogrel resistance 307
cardiovascular disease
atrial fibrillation 282
heart failure 282
risk factors 230, 231
risk of arterial thrombosis 230, 231
cardiovascular medicine 282–295
acute coronary syndromes 282–288
atrial fibrillation ablation 293–294
coronary artery disease (CAD) 282
electrophysiological catheter ablation 293–294
ehemostatic management challenges 282
peripheral arterial disease 288–290
transaortic valve replacement 294–295
ventricular assist devices 290–293
CHA2DS2VASc scoring system 230, 235
CHADS2 scoring system 230, 235
Chédiak–Higashi syndrome 48, 55, 65, 164, 165, 169
chronic kidney disease (CKD) see renal disease
Churg–Strauss disease see eosinophilic granulomatosis with polyangiitis (EGPA)
circumcision, bleeding with 63
clopidogrel 285, 286, 289–290
and aspirin 307
clopidogrel resistance 307
cardiovascular disease
atrial fibrillation 282
heart failure 282
risk factors 230, 231
risk of arterial thrombosis 230, 231
cardiovascular medicine 282–295
acute coronary syndromes 282–288
atrial fibrillation ablation 293–294
coronary artery disease (CAD) 282
electrophysiological catheter ablation 293–294
ehemostatic management challenges 282
peripheral arterial disease 288–290
transaortic valve replacement 294–295
ventricular assist devices 290–293
CHA2DS2VASc scoring system 230, 235
CHADS2 scoring system 230, 235
Chédiak–Higashi syndrome 48, 55, 65, 164, 165, 169
chronic kidney disease (CKD) see renal disease
Churg–Strauss disease see eosinophilic granulomatosis with polyangiitis (EGPA)
circumcision, bleeding with 63
clopidogrel 285, 286, 289–290
and aspirin 307
clopidogrel resistance 307

computed tomographic pulmonary angiography (CTPA) 201–202
direct oral anticoagulants 253–266 see also novel oral anticoagulants
direct thrombin inhibitors 254–256
direct thrombin inhibitors 253–254, 255, 325–326, 406
drug-induced thrombocytopenia 148–149
dysfibrinogenemia 116
in liver disease 332, 335
dysprothrombinemia 116
dysregulation of fibrinolysis 174–175
end-organ dysfunction 175
etiology 172–173
excessive activation of coagulation 173–174
microangiopathic hemolytic anemia 173
nonovert DIC 176–177
overt DIC 176
pathogenesis 173–175
scoring systems for DIC diagnosis 176–178
sepsis syndromes 175, 178
synonyms 172
treatment 178–181
antifibrinolytic therapy 180
antithrombin 180
management of the underlying disease 178–179
recombinant human activated protein C 180
recombinant soluble thrombomodulin (TM) 180–181
specific inhibitors of coagulation 180–181
supportive care and blood products 179
systemic anticoagulation 179–180
versus trauma-induced coagulopathy 175
dependent vein thrombosis (DVT) 200
direct thrombin inhibitors 253–254, 255, 325–326
dissemated intravascular coagulation (DIC) 138, 151, 172–181, 331, 418
critical care see intensive and critical care
diabetes testing 68, 199–200, 203
dabigatran 235, 253–254, 255, 293–294, 324–326, 405
see also direct oral anticoagulants
dalteparin 402–403
danaparoid 406
deep vein thrombosis (DVT) see also venous thromboembolism (VTE)
associated with liver disease 333–334
dengue virus 135
dental procedures, bleeding with 63
dilute Russell viper venom time (DRVVT) 16
dipyridamole 218
direct factor Xa inhibitors 254–256
direct oral anticoagulants 253–266 see also novel oral anticoagulants
acute coronary syndromes 264–265
direct factor Xa inhibitors 254–256
direct thrombin inhibitors 253–254, 255, 325–326, 406
evidence based clinical indications 256–265
extended treatment of VTE 261–263
future directions 266
interruption for elective procedures 266
laboratory assessment 265
pharmacology 253–256
practical considerations 265–266
reversal for surgery or major bleeding 266
stroke prevention in atrial fibrillation 263–264
treatment of acute VTE 259–261
VTE prevention in joint replacement surgery 256–259
VTE prevention in medically ill patients 259
direct thrombin inhibitors 253–254, 255, 325–326
for pediatric patients 406
disseminated intravascular coagulation (DIC) 138, 151, 172–181, 331, 418
critical care see intensive and critical care
conditions associated with 172–173
definition 172
diagnosis 176–178
downregulation of physiological anticoagulation pathways 174
dysregulation of fibrinolysis 174–175
end-organ dysfunction 175
etiology 172–173
excessive activation of coagulation 173–174
microangiopathic hemolytic anemia 173
nonovert DIC 176–177
overt DIC 176
pathogenesis 173–175
scoring systems for DIC diagnosis 176–178
sepsis syndromes 175, 178
synonyms 172
treatment 178–181
antifibrinolytic therapy 180
antithrombin 180
management of the underlying disease 178–179
recombinant human activated protein C 180
recombinant soluble thrombomodulin (TM) 180–181
specific inhibitors of coagulation 180–181
supportive care and blood products 179
systemic anticoagulation 179–180
versus trauma-induced coagulopathy 175
drug-induced thrombocytopenia 148–149
dysfibrinogenemia 116
in liver disease 332, 335
dysprothrombinemia 116
ecto-ADPase (CD39) 1
eculizumab 191, 192
edoxaban 235, 254, 255
see also direct oral anticoagulants
Ehlers–Danlos syndrome 66, 167
electron microscopy analysis of platelets 70
platelet function testing 54–55
electrophysiological catheter ablation, cardiac arrhythmias 293–294
endstage renal disease (ESRD), see renal disease
enoxaparin 286–287, 400, 402
see also direct oral anticoagulants
eosinophilic granulomatosis with polyangiitis (EGPA) 346–347
epsilon-aminocaproic acid 106–107, 169
Epstein–Barr virus 135, 138
Epstein syndrome 70
eptifibatide 286
erythropoiesis-stimulating agents (ESAs) 341–342
erythropoietin 439
essential thrombocythemia characteristics 210, 211
clinical manifestations 211–212
diagnosis 212–215
diagnostic criteria 212–214
molecular testing 212–215
pathophysiology of thrombotic and hemorrhagic complications 215
patient resources 225
perioperative management 225
testing thrombosis patients for a MPN 215, 216
thrombosis and hemorrhage risk 210
treatment established thrombosis 222–223
general approach 215–222
hemorrhage prevention and management 223
pregnant patient 223–224
specifics 222–225
use of hormone replacement therapy 224
use of oral contraceptives 224
estrogens 107
ethylenediaminetetraacetic acid (EDTA) 135
ethylenediaminetetraacetic acid (EDTA)-dependent antibodies 416
euglobin clot lysis time (ECLT) 68–69
Evan syndrome 148
factor II, deficiency 119
factor V 4, 8
deficiency 114, 116
evaluation 8–9
and factor VIII combined deficiencies 113, 114, 116
factor V Leiden mutation 8, 196, 321
molecular diagnostics 37–38
testing 21–23
factor Va 4, 7–8
factor VII 2
deficiency 113, 114, 116–117, 119
evaluation 8–9
factor VIIa, use in hemorrhage in nonhemophilia patients 309–310
factor VIII 4
deficiency 7, 113, 114, 116
evaluation 9
and factor V combined deficiencies 113, 114, 116
factor VIII (F8) gene 28
mutation in hemophilia A 28–31
factor VIIIa 6
factor IX 2–3
deficiency 7, 114, 119
evaluation 9
factor IX (F9) gene 27, 28
mutation in hemophilia B 31–32
factor IXa 4
factor X 2–3, 6
deficiency 113, 114, 117, 119
evaluation 8–9
factor Xa 4, 6, 7
factor Xa inhibitors 325, 326
for pediatric patients 406
factor XI 7
deficiency 113, 114, 117–118
evaluation 9
factor XII 9
factor XIII deficiency 63, 114, 118–119
testing 21, 68
familial platelet disorder with predisposition to acute myelogenous leukemia (FPD/AML) 48
familial platelet disorder with propensity for myeloid malignancy (FPD/AML) 139
familial thrombocytopenia 2 (THC2) 48
Fechtner syndrome 70
fibrin plug formation 6–7
fibrinogen 7
assays 68
deficiency 114–116
test 14–15
fibrinolytic inhibitors 169
fibrinolytic system assessment 68–69
fibrinopeptides 7
Index

FLNA-related thrombocytopenia 140
flow cytometry, platelet function testing 55–58
focal segmental glomerulosclerosis (FSGS) 344–346
fondaparinux 240, 286, 287, 406 see also heparins
properties of 241–242

fondaparinux 240, 286, 287, 406 see also heparins
properties of 241–242

focal segmental glomerulosclerosis (FSGS) 344–346
fondaparinux 240, 286, 287, 406 see also heparins
properties of 241–242

G

Glanzmann thrombasthenia 36, 47, 54, 56, 57, 64, 70, 162, 169
glucose-6-phosphate deficiency 167
β2-glycoprotein I 1, 272–273
GPLa/IIa (α2/β1) abnormalities 162
glycoprotein Iib/Illa receptor inhibitors 285–286
GPLlb/IIa (αIIb/β3) abnormalities 162
GPVI abnormalities 162–163
granulomatosis with polyangiitis (GAP) 346–347
gray platelet syndrome 48, 55, 139, 145, 156, 165

h

hantavirus 138
HAS-BLED bleeding risk scoring system 235
heart failure 282
hemolytic uremic syndrome (HUS) 138, 152, 185
hemophilia A 7 see also hemophilia A/B
acquired hemophilia A 91 association with hemorrhagic strokes 324
molecular diagnostics 31–32
mutations of particular clinical significance 32
polymorphism linkage analysis 31
Hemophilia B Mutation Database 32
hemostasis, definition 1
heparin-induced thrombocytopenia 31–32
mutations of particular clinical significance 32
polymorphism linkage analysis 31
Hemophilia B Mutation Database 32
hemostasis, definition 1
heparin-induced thrombocytopenia 56, 57, 138, 149, 419–423
heparin-induced thrombocytopenic thrombosis (HIT) 419–423
heparins 240–244 see also low-molecular weight heparins (LMWHs)
anticoagulant and antithrombotic properties 240–242
features of 240–242
major general surgery 242
major orthopedic surgery 242
medical patients 242
neutralization 242
pediatric patients 398–403
prophylaxis of VTE 242
treatment of arterial diseases 243–244
treatment of VTE 242–243
acute phase 242–243
long-term treatment 243
unfractionated heparin (UFH) 286, 287, 398–402
hepatic vein thrombosis 332–333
hepatitis B infection, related to transfusions 90
hepatitis C infection, related to transfusions 90
hepatitis C virus (HCV) 138
hepatitis C virus (HCV)-associated thrombocytopenia 151
heritable thrombophilia testing 21–23
Hermansky–Pudlak syndrome 47, 51, 55, 65, 70, 164–165
hexokinase deficiency 167
Heyde syndrome 427
HIV-associated thrombocytopenia 151
HIV infection
HAART therapy 89–90
related to transfusions 89–90
thrombocytopenia 135, 138
hormone replacement therapy (HRT) 64, 224, 389–390
Human Genome Project 28
hydroxyurea 218–220, 221, 224
hypercoagulable states, association with ischemic stroke 321–324
hyperfibrinolysis 68–69, 427
in liver disease 332, 335
hyperhomocysteinemia 39, 321, 322
hypersplenism 152
hypoprothrombinemia 116
i
ICU see intensive and critical care
idiopathic thrombocytopenic purpura (ITP) 417
immune thrombocytopenia (ITP) 135, 145–148, 418
immune thrombocytopenic purpura see immune thrombocytopenia (ITP)
in vitro fertilization (IVF) preimplantation genetic diagnosis 82
risk of thrombosis 379, 390
influenza 138
inherited coagulation disorders see hemophilia; rare inherited coagulation disorders; von Willebrand disease
inherited platelet disorders 36–37
inherited resistance to activated protein C (factor V Leiden) 37–38
intensive and critical care 414–429
fibrinolytic bleeding 427
heparin-induced thrombocytopenia 419–423
hyperfibrinolysis 427
incidence of hemostatic problems 414
inherited and acquired von Willebrand disease 427
Jehovah’s Witnesses 428–429
laboratory findings in hemostatic disorders 414, 415
management of thromboembolism 423–424, 425
managing coagulopathies 414–416
massive pulmonary embolism 423–424, 425
platelet clumping in patients with sepsis 416
renal failure 427
renal transplantation and thrombosis 427–428
sepsis 416–417, 419
septic thrombocytopenia 416–417
sequential organ failure assessment (SOFA) score 419, 420
special situations 427–429
systemic inflammatory response syndrome (SIRS) 419
thresholds for platelet transfusion 417–418
thrombocytopenia 416–418
thrombocytosis 423
thromboprophylaxis 424–427
### Janus kinase–signal transducer and activator of transcription (JAK-STAT) 210
- JAK-STAT inhibitors 219, 221

### Japanese Association for Acute Medicine, DIC score 177

### Jehovah's Witnesses
- Preoperative assessment 311

### Joint hypermobility 66

### kallikrein–kinin system 9

### Kasabach–Merritt syndrome 151–152

### Kidney biopsy 342–343
- Bleeding risk 342–343
- Prevention of bleeding 343

### Laboratory tests of hemostasis 12–25
- Assay issues in screening tests 17–19
- Clotting factor assay design 19–21
- Coagulation screening tests 14–16
- Establishment of local reference or normal range 23
- External quality assessment 25
- Factor XIII testing 21
- Factor assays to monitor replacement therapy in hemophilia 20–21
- Internal quality control 23, 25
- Mixing studies 16–19
- One-stage assays 19–20
- Quality assurance 23, 25
- Sample collection 12–13
- Anticoagulant and sample filling 13
- Container 13
- Mixing with anticoagulant 13

### Tests of fibrinolysis 12

### Venous catheters 12

### Sample processing and storage prior to analysis 13–14

### Centrifugation 13–14

### Stability 14

### Thrombophilia testing 21–23

### Liver biopsy 336

### Liver disease 329–338
- Acute liver failure 329
- Association with bleeding 329–330
- Bleeding 332
- Cholestasis 335
- Chronic liver disease 329
- Classification 329
- Clinical manifestations 329
- Clinical manifestations of coagulopathy 332–334
- Disseminated intravascular coagulation (DIC) 331
- Dysfibrinogenemia 332, 335
- Effects on hemostasis 329–330
- Effects on platelet function 168
- Evidence for rebalanced coagulation 335–336
- Extracorporeal circuits 334
- Fibrinogen level 335
- Hyperfibrinolysis 332, 335
- Impaired coagulation factor synthesis 330
- And invasive procedures 336–337
- Laboratory investigation of hemostasis 334–335
- Liver biopsy 336
- Liver transplantation 336–337
pathophysiology of coagulopathy 330–332
platelet dysfunction 331
progression of fibrosis due to parenchymal extinction 334
shunt insertion 336
signs of 65–66
thrombocytopenia 135, 330–331
thrombosis 332–334
thrombotic events 329–330
treatment of coagulopathy 337–338
vitamin K deficiency 331–332, 335
liver transplantation coagulopathies 336–337
treatment of coagulopathies 337
low-molecular weight heparins (LMWHs) 240, 286–287 see also heparins
antithrombotic properties 241–242
biochemical and pharmacological properties 241–242
features of 241–242
neutralization 242
pediatric patients 400, 402–403
lumiaggregometry 69–70
lupus anticoagulants see antiphospholipid syndrome
May–Hegglin anomaly 48, 70
measles 135
medications, effects on platelet function 168
membranoproliferative glomerulonephritis (MPGN) 344–346
membranous nephropathy 344–346
meningococcemia 138
menorrhagia 64, 107
microangiopathic hemolytic anemia (MAHA) 183
microangiopathies 151–152
microscopic polyangiitis (MPA) 346–347
minimal change disease 344–346
minimally invasive direct coronary artery bypass (MIDCAB) 300
mixing studies 16–19, 67–68
molecular diagnostics 27–40
antithrombin deficiency 38, 39
cloning of coagulation factor genes 28
future applications in hemostasis 39–40
hemophilia A 28–31
hemophilia B 31–32
history of approaches to bleeding disorders 28
inherited platelet disorders 36–37
inherited resistance to activated protein C (factor V Leiden) 37–38
less common inherited coagulation factor deficiencies 36
myeloproliferative neoplasms 212–215
protein C deficiency 38, 39
protein S deficiency 38, 39
prothrombin gene 20210 3’ noncoding sequence variant 38
responses to oral anticoagulation 39
thermolabile C677T 5,10-MTHFR variant 38–39
thrombotic disease 37
von Willebrand disease (VWD) 32–36
MTHFR gene, thermolabile C677T variant 38–39
Munchausen syndrome 65
multiple organ dysfunction syndrome (MODS) 415
mumps 135
myelodysplastic syndromes, bleeding complications 167
myelophthisis 135–136
myeloproliferative disorders (MPD) 44
Budd–Chiari syndrome (BCS) 333
thrombotic and hemorrhagic complications 167–168
myeloproliferative neoplasms 210–225
characteristics 210, 211
clinical manifestations 210–212
diagnosis 212–215
diagnostic criteria 212214
molecular testing 212–215
pathophysiology of thrombotic and hemorrhagic complications 215
patient resources 225
perioperative management 225
testing thrombosis patients for an MPN 215, 216
thrombosis and hemorrhage risk 210
treatment established thrombosis 222–223

M
macrothrombocytopenia 55
magnetic resonance angiography (MRA), suspected PE 203
magnetic resonance venography (MRV)
suspected DVT 200
venous sinus thrombosis 316–317
Marfan syndrome 167
myeloproliferative neoplasms (Cont.)
general approach 215–222
hemorrhage prevention and management 223
pregnant patient 223–224
specifics 222–225
use of hormone replacement therapy 224
use of oral contraceptives 224
MYH9-related disease (MYH9-RD) 139, 155
myocardial infarction 282–288
near-patient testing
early attempts 303–304
need for 303
transfusion algorithms based on 305–307
neonatal alloimmune thrombocytopenia (NAIT) 138, 153–154
neonatal autoimmune thrombocytopenia 154
neonatal purpura fulminans 39
neonatal thrombocytopenia 152–156
neonate with hemophilia 83
neonates, transfusion 441–442
nephrotic syndrome see renal disease
neurological complications 314–326
intracerebral hemorrhage (ICH) 314, 315, 317–320, 324
ischemic stroke 314–316, 321–324
management of anticoagulant-related bleeding 325–326
novel anticoagulant agents 324–326
subarachnoid hemorrhage (SAH) 314, 316, 320
venous sinus thrombosis (VST) 314, 316–317
nitric oxide (NO) 1
non-ST-elevation myocardial infarction (NSTEMI) 282–288
novel anticoagulant agents 324–326 see also direct oral anticoagulants
management of anticoagulant-related bleeding 325–326
reversal of agents 325–326
obstetrics see pregnancy
oculocutaneous albinism 65
off-pump coronary artery bypass (OPCAB) 300
oral anticoagulants see direct oral anticoagulants;
vitamin K antagonists
oral contraceptives, risk of VTE 64, 224, 379, 388–389
oral vitamin K antagonists, pediatric patients 400, 403–406
osteogenensis imperfecta 167
otopalatodigital syndrome 48
ovarian hyperstimulation, risk of thrombosis 390

P
$^{32}$P 218
P2Y$_{12}$ receptor
abnormalities 163–164
pancytopenia 135, 137
PAR1 4
PAR4 7
Paris–Trousseau syndrome 48, 139, 165
parvoviruses 135
infection related to transfusions 90
pediatric patients, transfusion 441–442
pediatric thrombosis 393–409
antithrombotic therapy 398–408
dalteparin 402–403
direct thrombin inhibitors 406
duration and intensity 406–407
enoxaparin 400, 402–403
factor Xa inhibitors 406
heparin 398–403
low molecular weight heparin (LMWH) 400, 402–403
new agents 406
oral vitamin K antagonists 400, 403–406
patient self-management 405–406
patient self-testing (PST) 405, 406
phenprocoumon 403
specific challenges in pediatric patients 398
thrombolytic therapy 407
tinzaparin 400, 402–403
unfractionated heparin (UFH) 398–402
warfarin 400, 403–406
arterial thrombosis 396
challenges for health professionals 393
cohorts of children at risk 394–395
congenital heart disease risk factor 395, 396
deep venous thrombosis 396
depvelopmental hemostasis 393–394
diagnosis 396–397
differences to adult practice 393
difficulties of clinical trials involving children 409
epidemiology 397
future perspectives 409
health-related quality of life (HRQOL) 398
hemostatic differences in children 394
importance of antithrombotic therapy 397
incidence of thrombosis in children 393
indications for anticoagulation 396
long-term anticoagulation in children 396
normal hemostasis in children 393–394
outcomes 397
post-thrombotic syndrome 397
pulmonary embolism 396
risk factors 394–395
sequelae of asymptomatic clots 397
systemic arterial thrombosis outcomes 397
therapeutic agents and metabolism 397–398
thrombophilia testing in children 408–409
percutaneous transluminal angioplasty (PTA) 290
pericytes 4
peripheral arterial disease 288–290
antiplatelet and anticoagulant therapy 289–290
cardiovascular risk 288–289
cardiovascular risk reduction 289–290
drug therapy after revascularization 290
epidemiology 288
percutaneous transluminal angioplasty (PTA) 290
periventricular nodular heterotopia 48
phenprocoumon 244, 402 see also vitamin K antagonists
phlebotomy 217–218 224
phosphatidylserine 4
pipobroman 218
platelet activation 4–5, 43–44
platelet aggregation and clot formation 43–44
testing 69–70
platelet disorders see also platelet function disorders
inherited platelet disorders 36–37
quantitative see thrombocytopenia
platelet-driven thrombin generation 4–5
platelet function in healthy endothelium 1
hemostatic plug formation 42–44
normal function 42–46
platelet function analysis, use of ROTEM and TEG 307
platelet function analyzer (PFA-100® / PFA-200®) 50–51, 69
platelet function disorders 166–167
acquired platelet defects 167–168
classification of platelet defects 44, 46–49
congenital disorders 160–167
in liver disease 331
primary secretion defects 166
treatment options 169
platelet function testing 46, 50–58, 69–70
bleeding time 50
challenges 50
diagnostic tests 51–58
electron microscopy 54–55
flow cytometry 55–58
global tests 50–51
light transmission platelet aggregometry 51–53, 54
patient history 46
platelet function analyzer (PFA-100® / PFA-200®) 50–51, 69
PlateletMapping™ system 58
Plateletworks® 58
range of tests 46
Thromboelastography® (TEG) 58
VerifyNow® device 58
whole-blood aggregometry 53, 54
platelet granules 4
α-granules 95
α-granule abnormalities 165
δ-granule abnormalities 165
δ-granule abnormalities (δ-storage pool deficiency) 164–165
platelet membrane phospholipid abnormalities 166
platelet organelles 43
platelet production 134–135
platelet receptor abnormalities for adhesive proteins 161–163
for soluble agonists 163–164
platelet signal-transduction pathway abnormalities 166
platelet structure 42, 43
platelet surface thrombin generation 6–7
platelet transfusions 169
platelet-type von Willebrand disease 36–37, 47, 54, 139, 162, 169
PlateletMapping™ system 58
Plateletworks® 58
pneumococcal HUS 187, 189
point-of-care thromboelastography (TEG) 303–304
polycythemia vera and Budd–Chiari syndrome (BCS) 333
pseudothrombocytopenia 416
pulmonary angiography 200–201
pulmonary embolism (PE)  see also venous thromboembolism (VTE) associated with liver disease 333–334
purpura fulminans 39, 175

q
qualitative platelet disorders 160–169
quality assurance in laboratory testing 23, 25
Quebec platelet disorder 48, 51, 165, 169

r
radioulnar synostosis with amegakaryocytic thrombocytopenia 139
rare inherited coagulation disorders 113–121
afibrinogenemia 115–116
clinical features 114–115
dysfibrinogenemia 116
dysprothrombinemia 116
factor II deficiency 119
factor V deficiency 114, 116
factor V and VIII combined deficiencies 113, 114, 116
factor VII deficiency 113, 114, 116–117, 119
factor VIII deficiency 113, 114, 116
factor IX deficiency 114
factor X deficiency 113, 114, 117, 119
factor XI deficiency 113, 114, 117–118, 119
factor XIII deficiency 114, 118–119
fibrinogen deficiency 114–116
genetics 114
hypoprothrombinemia 116
illustrative case histories 119–121
individual deficiencies 115–119
investigation 115
nature of the rare inherited disorders 113–114
pregnancy 115
prothrombin deficiency 114, 116
risk associated with consanguinity 114, 120–121
vitamin K-dependent clotting factors deficiency (VKCFD) 113, 119
recombinant activated factor VII 439
renal disease 340–351
ANCA vasculitis and venous thromboembolism 346–347
anticoagulant use 349–351
anticoagulants 349–351
guidelines for mild to moderate renal insufficiency 349–350
guidelines for severe renal insufficiency 350
oral anticoagulants 350–351
bleeding in 340–342
clinical presentation 340
etiology of bleeding 340–341
gastrointestinal (GI) bleeding 340
prevention of bleeding 341–342
treatment of bleeding 341–342
kidney biopsy 342–343
renal vein thrombosis 347–348
thrombosis in chronic kidney disease 343–344
clinical presentation 343
etiology 343–344
prevention 344
treatment 344
thrombosis in nephrotic syndrome 344–346
etiology 345
treatment 345–346
renal failure, intensive and critical care patients 417
renal transplantation and thrombosis 348–349, 427–428
renal vein thrombosis 347–348
reptilase time 16, 67
rivaroxaban 235, 254–255, 293–294, 324–326, 405
see also direct oral anticoagulants
robot-assisted coronary artery bypass (RACAB) 300
ROTEM (rotational thrombelastometry) 305
extended uses 307
platelet function assessment 307
ROTEM-based transfusion algorithms 307
rubella 135, 138
ruxolitinib 219, 221, 222
s
Scott syndrome 48, 57, 166, 169
scurvy 65
Sebastian–Fechtner–Epstein syndrome 48
Sebastian syndrome 70
senile purpura 65
sepsis syndromes, association with DIC 175, 178
sequential organ failure assessment (SOFA) score 419, 420
shiga-like toxin-associated hemolytic uremic syndrome (STEC-HUS) diagnosis 188
Index

t
Index

467

diagnosis 188–189
differential diagnosis 183, 184
microangiopathic hemolytic anemia (MAHA) 183
outcomes 191–192
pathophysiology 184–187
thrombocytopenia 183
treatment 189–191
thrombotic thrombocytopenic purpura (TTP) 152, 183, 184
diagnosis 183–184, 188
outcomes 192
pathophysiology 184

treatment 189–190
thromboxane 44
thromboxane A₂ receptor abnormalities 163
ticagrelor 285, 286
ticlopidine 285
tinzaparin 400, 402–403
tirofiban 286
tissue factor
distribution and levels throughout the body 2
functions 2, 3
hemostatic envelope 2
tissue factor pathway inhibitor (TFPI) 4, 6, 7
tranexamic acid 88, 106–107, 169, 309, 439
tansaortic valve replacement 294–295
bleeding in 294
clinical experience 294
stroke associated with 294
surgical heart valve replacement and repair 294–295
transfusion 433–443
ABO blood group
system 433–434
after cardiac surgery 299
antibody screening 434
blood products available 436–439
autologous blood 438–439
coaulation factor concentrates 438
cryosupernatant and methylene blue-treated cryosupernatant 438
cryoprecipitate and methylene blue-treated cryosupernatant 438
fibrin sealants 438
fresh frozen plasma (FFP) 437
human albumin solution 438
intravenous immunoglobulin 438
platelets 437
red cells 436–437
blood transfusion as a form of transplantation 433–434
cardiac surgery 441
clinical indications to reduce exposure 308
dilutional thrombocytopenia 135
drugs that reduce the need for 439
following cardiothoracic surgery 302–305
hemovigilance and regulation of transfusion 442–443
importance of good communication between health professionals 441
in disseminated intravascular coagulation 441
indications to reduce exposure 308
infective risks 435
issues for Jehovah's Witnesses 428–429, 442
logistical indications to reduce exposure 308
massive transfusion 441
near-patient testing-based transfusion algorithms 305–307
neonates 441–442
obstetrics 441
pediatric patients 441–442
pharmacotherapy to minimize blood loss and transfusion 308–310
reactions to 435–436
delayed hemolytic reactions 436
febrile transfusion reactions 436
immediate hemolytic reactions 435–436
immunization 436
post-transfusion purpura 436
transfusion-related acute lung injury (TRALI) 415, 436
red cell blood group systems 433–434
red cell cross-matching 434
Rhesus blood group system 434
risks of transfusion 435
safe transfusion practice 442–443
Serious Hazards of Transfusion (SHOT) scheme 442–443
special situations 441–442
thrombocytopenia related to 142
use of blood products 440–441
assessment of hemorrhage 440
how much to give 440
near patient testing 440
use of O-negative blood 434
transfusion-associated infections 142, 150
transfusion-related acute lung injury (TRALI) 415, 436
transient ischemic attacks (TIAs) 315, 316
TUBB1-related thrombocytopenia 139
umbilical stump bleeding  63
unfractionated heparin (UFH)  286, 287
pediatric patients  398–402
unstable angina  282–283
uremia  167 see also renal disease
variant Creutzfeldt–Jakob disease (vCJD)  90, 308, 435
varicella  135, 138
vasculature, features of healthy vasculature  1–2
venography  197
venous sinus thrombosis (VST)  314
acute treatment  317
definition  316
diagnosis  316–317
etiologies  317
magnetic resonance venography (MRV)  316–317
prognosis  317
treatment  317
venous thromboembolism (VTE)  195–208
acquired predisposition to  196
advice to patients after negative testing  204
in ANCA vasculitis  346–347
associated with liver disease  333–334
diagnosis of DVT  196–200
diagnosis of DVT in pregnancy  200
diagnosis of PE  200–204
diagnosis of PE in pregnancy  203
diagnosis of recurrent DVT  200
diagnosis of VTE  196–204
inherited predisposition to  195–196
management  196–204
natural history  196
nondiagnostic combinations of noninvasive tests for PE  203
pathogenesis  195–196
prevalence  196
prevention/
prophylaxis  207–208
following surgery  207–208
in joint replacement surgery  256–259
in medical patients  208, 259
risk factors  195–196
treatment  204–207
active malignancy  205
acute VTE  259–261
duration of anticoagulant therapy  204–205
during pregnancy  206
extended treatment of VTE  261–263
hypercoagulable states  205–206
inferior vena caval filters  207
initiation of anticoagulant therapy  204
long-term therapy with vitamin K antagonists  204
major transient risk factors  205
minor transient risk factors  205
novel oral anticoagulants  204
risk of bleeding on anticoagulant therapy  206
risk of recurrent VTE  205–206
surgical treatment  207
thrombolytic therapy  206–207
unprovoked VTE  205
venous ultrasonography  197–199
ventilation–perfusion lung scanning  202
ventricular assist devices (VADs)  290–293
balancing VAD-related thromboembolic and bleeding risk  292–293
bleeding in continuous-flow VADs  291
HeartMate II device  290–291
ISHLT guidelines  293
left ventricular assist devices (LVADs)  290
management of bleeding in continuous-flow VADs  291–292
management of VAD thrombosis  292
VerifyNow® device  58
vitamin K (phytonadione) administration  248
vitamin K antagonists (VKAs)  240
anticoagulation reversal  248
bleeding complications  246–248
clinical management of overanticoagulation and bleeding  249
features of  244
initiation and dosing of warfarin anticoagulation  245–246
management of anticoagulated patients who require surgery or invasive procedures  249–251
management of overanticoagulation and bleeding  248–249
oral anticoagulants  244–251
patients with highly unstable response  246
postoperative management of anticoagulation  251
replacement of deficient clotting factors  248–249
risk of intracranial hemorrhage  246–248
use in arterial thrombosis  235, 236
use in atrial fibrillation  235, 236
vitamin K deficiency, associated with liver disease  331–332, 335
vitamin K-dependent clotting factors deficiency (VKCFD)  113, 119
vitamin therapy  439
von Willebrand disease (VWD)  94–109
classification  95–96
clinical manifestations  99
diagnosis  99–105
bleeding history  100–102
bleeding score  100–102
laboratory evaluation  100, 103–105
subtype characterization  103–105
genetics  96–98
intensive and critical care patients  427
molecular biology  96–98
molecular diagnostics  32–36
patient management  105–109
antifibrinolytic amino acids  106–107
desmopressin  105–106, 108
epsilon aminocaproic acid  106–107
estrogens  107
non-transfusional therapies  105–107
practical approach to treatment  108
secondary long-term prophylaxis  108–109
tranexamic acid  106–107
transfusional therapies  107–108
women of childbearing age  109
physiological role of VWF  95
platelet function testing  51, 54
platelet-type VWD (PT-VWD)  36–37, 47, 54, 139, 162, 169
prevalence and frequency of subtypes  98–99
testing  68
type 1 VWD  35–36
type 2 VWD  33–34
type 2A VWD  34
type 2B VWD  34
type 2M VWD  34–35
type 2N VWD  35, 64
type 3 VWD  33
types and subtypes  95–96
von Willebrand factor (VWF)  3, 4, 94–95
see also VWF gene
VWF gene  94
mutations  32–36, 96–98
polymorphism  33
structure  32–33
VWF mutation database  33

W
warfarin  244, 325 see also vitamin K antagonists
genetic influences on response to  39
pediatric patients  400, 403–406
peripheral arterial disease  290
use in pregnancy  386
Wegener granulomatosis see granulomatosis with polyangiitis (GAP)
Weibel–Palade bodies  95
whole-blood aggregometry  53, 54, 70
Wiskott–Aldrich syndrome  48, 140, 156, 165, 169

X
X-linked dyserythropoietic anemia and thrombocytopenia  48
X-linked thrombocytopenia  48, 140, 156
X-linked thrombocytopenia with dyserythropoiesis  140